ReviewBreast cancer research and treatment2010
Papillary carcinoma of the breast: an overview.
Review in Breast cancer research and treatment, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.
- Diagnostic Accuracy of Nipple Discharge Fluid Cytology: A Meta-Analysis and Systematic Review of the Literature.Annals of surgical oncology · 2022Pooled it
- Utilization of NKX3.1 and P501S to distinguish primary breast carcinoma from metastatic prostatic adenocarcinoma in male patients.Virchows Archiv : an international journal of pathology · 2026Article
- Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study.The oncologist · 2026Article
- Multilevel classification framework for breast cancer cell selection and its integration with advanced disease models.iScience · 2025Review
- A compendium of male breast imaging: The road less traveled.World journal of radiology · 2025Review
- Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.Histopathology · 2025Review
- Risk Stratification for Sentinel Lymph Node Positivity in Older Women With Early-Stage Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Neu-Negative Invasive Breast Cancer.JCO clinical cancer informatics · 2025Article
- Addition of contrast-enhanced mammography enhancement patterns and morphology for differentiating benign from malignant papillary breast lesions.The British journal of radiology · 2025Article
- Untangling Breast Cancer: Trailing Towards Nanoformulations-based Drug Development.Recent patents on nanotechnology · 2025Review
- Rare Breast Cancers Review.Healthcare (Basel, Switzerland) · 2024Review
- Article
- Article
- Invasive papillary carcinoma of the breast: A case report.Oncology letters · 2024Article
- Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations.Current breast cancer reports · 2024Article
- Macroscopic inelastic scattering imaging using a hyperspectral line-scanning system identifies invasive breast cancer in lumpectomy and mastectomy specimens.Journal of biomedical optics · 2024Article
- Article
- Rare Breast Cancer Histotypes-A Retrospective Study and Literature Review.Journal of clinical medicine · 2024Article
- Invasive papillary carcinoma of the breast.Frontiers in oncology · 2024Review
- Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health.BioMed research international · 2024Review
- Male Breast: A Review of the Literature and Current State of the Art of Diagnostic Imaging Work-Up.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Papillary carcinoma of the breast represents approximately 0.5% of all newly diagnosed cases of breast cancer. The prevalence of both invasive and in situ papillary carcinoma seems to be greater in older postmenopausal women and, in relative terms, in males. Histologic features of the tumor include cellular proliferations surrounding fibrovascular cores, with or without invasion. In this review, characteristics of both in situ and invasive disease are outlined. Immunohistochemical analyses of papillary carcinoma suggest the utility of markers such as smooth muscle myosin heavy chain, calponin, p63, and high molecular weight keratins, which can characterize the myoepithelial cell layer. With respect to radiographic evaluation of papillary carcinoma, ultrasonography is the most extensively studied imaging modality, though magnetic resonance mammography has potential utility. Available data suggest improved outcome for papillary carcinoma as compared to invasive ductal carcinoma. Treatment-related information for patients with papillary carcinoma is limited, and patterns noted in available series suggest a variable approach to this disease. The scarcity of information underscores the need for further treatment- and outcome-related studies in papillary carcinoma of the breast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.